Literature DB >> 20527018

Anaplastic plasmacytoma of mouse--establishing parallels between subtypes of mouse and human plasma cell neoplasia.

Daphne de Jong1, Siegfried Janz.   

Abstract

Mouse models may provide an important tool for basic and applied research on human diseases. An ideal tumour model should replicate the phenotypic and molecular characteristics of human malignancy as well as the typical physiological effects and dissemination patterns. The histopathological and molecular genetic characterization of anaplastic plasmacytoma (APCT) in strain NSF.V(+) mice provides an example to achieve this goal for a specific lymphoma subtype. Firstly, it demonstrates that, like plasma-cell neoplasms in humans, those in mice occur as distinct subtypes. Secondly, it shows that mouse APCT exhibits striking parallels to possible human tumour counterparts for which good mouse models of de novo tumour development are sorely needed: IgM(+) multiple myeloma and Waldenström's macroglobulinaemia. Thirdly, it strongly suggests that insertional somatic mutagenesis, by either a murine leukaemia virus or an oncogenic transposon, would be an effective experimental approach to accelerating malignant transformation of mature B cells and plasma cells in mice and, thereby, tagging and uncovering cancer driver genes that may be of great relevance for the tumour initiation and progression in lymphoma. (c) 2010 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2010        PMID: 20527018      PMCID: PMC3118561          DOI: 10.1002/path.2714

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  53 in total

1.  Normal and pathologic anatomy of the reticular tissue in laboratory mice, with a classification and discussion of neoplasms.

Authors:  T B DUNN
Journal:  J Natl Cancer Inst       Date:  1954-06       Impact factor: 13.506

2.  Histologic classification and staging of multiple myeloma. A retrospective and prospective study of 674 cases.

Authors:  R Bartl; B Frisch; A Fateh-Moghadam; G Kettner; K Jaeger; W Sommerfeld
Journal:  Am J Clin Pathol       Date:  1987-03       Impact factor: 2.493

3.  Experimental models of lymphoproliferative disease. The mouse as a model for human non-Hodgkin's lymphomas and related leukemias.

Authors:  P K Pattengale; C R Taylor
Journal:  Am J Pathol       Date:  1983-11       Impact factor: 4.307

4.  V(H) gene analysis of IgM-secreting myeloma indicates an origin from a memory cell undergoing isotype switch events.

Authors:  S S Sahota; R Garand; R Mahroof; A Smith; N Juge-Morineau; F K Stevenson; R Bataille
Journal:  Blood       Date:  1999-08-01       Impact factor: 22.113

5.  The SCID-rab model: a novel in vivo system for primary human myeloma demonstrating growth of CD138-expressing malignant cells.

Authors:  K Yata; S Yaccoby
Journal:  Leukemia       Date:  2004-11       Impact factor: 11.528

6.  Possible roles for activating RAS mutations in the MGUS to MM transition and in the intramedullary to extramedullary transition in some plasma cell tumors.

Authors:  Thomas Rasmussen; Michael Kuehl; Marianne Lodahl; Hans E Johnsen; Inger Marie S Dahl
Journal:  Blood       Date:  2004-08-31       Impact factor: 22.113

7.  Induction of plasma cell tumours in BALB-c mice with 2,6,10,14-tetramethylpentadecane (pristane).

Authors:  P N Anderson; M Potter
Journal:  Nature       Date:  1969-06-07       Impact factor: 49.962

8.  Primary myeloma cells growing in SCID-hu mice: a model for studying the biology and treatment of myeloma and its manifestations.

Authors:  S Yaccoby; B Barlogie; J Epstein
Journal:  Blood       Date:  1998-10-15       Impact factor: 22.113

9.  An E mu-v-abl transgene elicits plasmacytomas in concert with an activated myc gene.

Authors:  H Rosenbaum; A W Harris; M L Bath; J McNeall; E Webb; J M Adams; S Cory
Journal:  EMBO J       Date:  1990-03       Impact factor: 11.598

10.  Spontaneous development of plasmacytoid tumors in mice with defective Fas-Fas ligand interactions.

Authors:  W F Davidson; T Giese; T N Fredrickson
Journal:  J Exp Med       Date:  1998-06-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.